Buscar
Congreso SOLACI

Búsqueda de: drug-eluting stents

Si no está conforme con los resultados, inténtelo de nuevamente.
Chronic Ischemic cardiopathy

Long-Term Results from the BEST Study: Drug-Eluting Stents vs. Bypass Surgery in Diabetic Patients with Multiple Vessel Disease

The impact of diabetes on the development of cardiovascular disease is widely known, with a strong association...
solaci -
Ir
Femoropopliteal

Drug-Eluting Stents vs. Balloons While Paclitaxel Is in the Eye of the Storm

Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients...
solaci -
Ir
Femoropopliteal

TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX,...
solaci -
Ir
Chronic Ischemic cardiopathy

IVUS vs. Angiography in New-Generation Drug-Eluting Stents Preimplantation

Courtesy of Dr. Guillermo Migliaro. The latest 2011 American College of Cardiology (ACC) guideline states that “coronary intravascular ultrasonography (IVUS)...
solaci -
Ir
Day 4

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences...
solaci -
Ir
Day 2

PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.

Summary: Randomized, open, pragmatic essay PROTECT (patient related outcomes of Endeavor versus Cypher stenting trial) compared two...
solaci -
Ir
Day 2

Emerging Bioabsorbable Stent and Balloon Platforms: Are the days of metallic drug-eluting stents numbered? 

Juan F. Granada 2012-08-09
solaci -
Ir
Coronary disease

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad